Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05803200 · ClinicalTrials.gov registry record
A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy
A clinical trial, sponsored by Takeda.
- Completed
- Registry status
- 7
- Enrollment target
NCT05803200: Completed study, sponsored by Takeda.
NCT05803200 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05803200 has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
The main aim of this study is to provide further information on the safety profile of HyQvia during pregnancy. This will be done by checking the characteristics of the mother and their babies. They will also be checked for any safety outcomes that will occur when exposed to HyQvia during pregnancy.
Primary Outcome
A major malformation is defined as a structural abnormality with surgical, medical, or cosmetic importance. Data for infants will be reviewed in the database from the date of delivery to 90 days following birth to check for any malformations. The number of infants with malformations during the database period of 1 January 2014 to 31 December 2020 (up to 7 years) will be reported.
Interventions
- DRUG No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2023-04-14 |
What the finished NCT05803200 record still lists
NCT05803200 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT05803200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05803200 about?
NCT05803200 is a clinical study titled "A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy". The main aim of this study is to provide further information on the safety profile of HyQvia during pregnancy. This will be done by checking the characteristics of the mother and their babies. They will also be checked for any safety outcomes that will occur when exposed to HyQvia during pregnancy.
What is the current status of trial NCT05803200?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2023-03-15. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT05803200?
The interventions under investigation include: No intervention (DRUG).
Who is sponsoring clinical trial NCT05803200?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI